BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 22924896)

  • 1. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
    Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
    Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database.
    Impicciatore P; Mucci M
    Drug Saf; 2010 Sep; 33(9):765-73. PubMed ID: 20701409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.
    Inch J; Watson MC; Anakwe-Umeh S
    Drug Saf; 2012 Oct; 35(10):807-18. PubMed ID: 22928729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Completeness of pharmacovigilance reporting in general medicine in France.].
    Humbert X; Jacquot J; Alexandre J; Sassier M; Robin N; Pageot C; Kheloufi F; Joyau C; Coquerel A; Durrieu G; Fedrizzi S
    Sante Publique; 2019; Vol. 31(4):561-566. PubMed ID: 31959257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of adverse drug reaction reports in South Africa: An analysis of VigiBase® for the year 2017.
    Steyn H
    S Afr Med J; 2023 Jun; 113(6):26-33. PubMed ID: 37278262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.
    Aldea A; García Sánchez-Colomer M; Fernández Quintana E; García Sáiz M
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1329-38. PubMed ID: 22415248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
    Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
    Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.
    Aagaard L; Nielsen LH; Hansen EH
    Drug Saf; 2009; 32(11):1067-74. PubMed ID: 19810778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
    Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
    Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of probabilistic method to detect duplicate individual case safety reports.
    Tregunno PM; Fink DB; Fernandez-Fernandez C; Lázaro-Bengoa E; Norén GN
    Drug Saf; 2014 Apr; 37(4):249-58. PubMed ID: 24627310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.
    van Hunsel F; de Waal S; Härmark L
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):977-983. PubMed ID: 28524293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports.
    Oosterhuis I; Rolfes L; Ekhart C; Muller-Hansma A; Härmark L
    Expert Opin Drug Saf; 2018 Feb; 17(2):111-115. PubMed ID: 29157026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases.
    Machado-Alba JE; Londoño-Builes MJ; Echeverri-Cataño LF; Ochoa-Orozco SA
    Biomedica; 2016 Mar; 36(1):59-66. PubMed ID: 27622439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
    Cliff-Eribo KO; Sammons H; Choonara I
    Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade.
    Tsuchiya M; Obara T; Miyazaki M; Noda A; Takamura C; Mano N
    Int J Clin Pharm; 2020 Apr; 42(2):728-736. PubMed ID: 32020439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.